Sonepcizumab (LT 1009) is a fully humanized monoclonal antibody against S1P, with anti-cancer activity, useful for studying metastatic renal cell carcinoma (mRCC) and preventing eye scarring after glaucoma filtration surgery.
CAS Number:
[1031360-18-5]
Target:
LPL Receptor
* VAT and and shipping costs not included. Errors and price changes excepted